24/7 Market News Snapshot 01 May, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)

May 1, 2025

DENVER, Colo., 01 May, 2025 (www.247marketnews.com) – (NASDAQ:RNAZ) are discussed in this article.
TransCode Therapeutics, Inc. (RNAZ) has witnessed a remarkable surge in its stock price, soaring by 45.6% to a current valuation of $0.592 during recent trading sessions. This escalation follows a previous closing price of $0.407, which reflects a substantial increase in investor interest, with a trading volume of approximately 14.39 million shares. The positive market response underscores growing enthusiasm surrounding the company’s innovative approaches to cancer treatment, particularly concerning its lead therapeutic candidate, TTX-MC138.

The company has also shared significant updates regarding its Phase 1a clinical trial of TTX-MC138, which is investigating the safety and efficacy of this pioneering treatment aimed at combating metastatic cancer through targeting microRNA-10b (miR-10b). To date, 13 patients have participated in the trial, advancing through four escalating doses without major safety concerns or dose-limiting toxicities. Encouragingly, two participants have maintained stable disease status for over seven months, highlighting the candidate’s potential effectiveness in managing metastatic cancers.

Pharmacodynamic analyses have revealed promising data, demonstrating target engagement with miR-10b in five out of six evaluated patients, confirming the expected therapeutic activity of TTX-MC138. With eight patients remaining in treatment cycles of 28 days, continual monitoring for safety and antitumor efficacy is ongoing. Preliminary outcomes resonate well with prior preclinical data and Phase 0 results, reinforcing confidence in the drug’s pharmacokinetic and pharmacodynamic profiles.

TransCode Therapeutics is committed to revolutionizing cancer care through its novel RNA therapeutics, particularly with the advancement of the TTX nanoparticle platform designed to enhance RNA delivery. As the trial progresses, further updates are anticipated, emphasizing the company’s strategic role in addressing the complexities of metastatic cancer treatment.

Related news for (RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.